J&J keeps Alzheimer's focus with Alector collaboration
This article was originally published in Scrip
Johnson & Johnson entered into a research collaboration with Alector, one of the companies in its biotechnology startup incubator in Northern California, to identify a therapeutic candidate against an undisclosed Alzheimer's disease target.
You may also be interested in...
Alector says upfront payment and earnouts will fully pay for development of AL101 and AL001 in frontotemporal dementia and indications including ALS, Alzheimer’s and Parkinson’s.
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
A bluebird executive spoke during ARM’s Cell and Gene Meeting On The Mesa about why the firm pulled Zynteglo out of the EU, but while progress has been made in the US, long-term challenges remain.